Showing results (171-180 of 188) with videos related to
Sort By:
Pageof 19
Neurology|May 22, 1998
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, N A Simonian, J A Alam, et al.Neurology|July 17, 1999
A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)J H Simon, L D Jacobs, M K Campion, et al.Advances in Therapy|May 5, 2019
Multiple Sclerosis Performance Test: Technical Development and UsabilityJane K Rhodes, David Schindler, Stephen M Rao, et al.Journal of Neurology|March 25, 2009
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELMichael Hutchinson, Ludwig Kappos, Peter A Calabresi, et al.Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.Neurology|July 26, 2000
A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research GroupJ H Simon, J Lull, L D Jacobs, et al.Neurology|April 22, 2024
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple SclerosisRobert J Fox, Bruce A C Cree, Jérôme de Sèze, et al.Neurology|April 18, 2007
Natalizumab reduces visual loss in patients with relapsing multiple sclerosisL J Balcer, S L Galetta, P A Calabresi, et al.Annals of Neurology|August 19, 2007
Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick, Deborah Miller, Steve Hass, et al.Annals of Neurology|December 16, 2000
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research GroupJ S Fischer, R L Priore, L D Jacobs, et al.Pageof 19